Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 24;16(5):835-844.
doi: 10.1093/ecco-jcc/jjab206.

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis

Ferdinando D'Amico  1   2 , Fernando Magro  3 , Laurent Peyrin-Biroulet  4 , Silvio Danese  2
Affiliations
Review

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis

Ferdinando D'Amico et al. J Crohns Colitis. .

Abstract

Background and aims: Filgotinib is a small molecule that selectively inhibits Janus kinase [JAK] type 1. It is already approved for the treatment of rheumatoid arthritis and is being evaluated for the management of patients with moderate to severe ulcerative colitis [UC]. The purpose of this review is to provide an overview of the currently available data on filgotinib and to define how to position this new drug in the treatment algorithm of patients with UC.

Methods: The Pubmed, Embase and Scopus databases were searched up to June 25, 2021 in order to identify studies reporting efficacy and safety data of filgotinib in patients with UC.

Results: Data from a phase III study enrolling UC patients with moderate to severe disease show that filgotinib is effective with a reassuring safety profile. Filgotinib treatment is not associated with a greater risk of thrombosis and herpes zoster infections compared to other JAK inhibitors. However, animal studies reported impaired spermatogenesis and histopathological effects on male reproductive organs, making it necessary to deepen this aspect in dedicated human studies.

Conclusions: Filgotinib is an effective and safe drug for treatment of both biologic-naive and biologic-experienced patients with moderate to severe UC and may soon be available.

Keywords: Filgotinib; JAK inhibitor; inflammatory bowel disease; small molecule; ulcerative colitis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Proposed algorithm for a tailored therapy with biologic agents or small molecules in moderate-to-severe UC. UC: ulcerative colitis; TNF: tumour necrosis factor. Dashed line: currently under investigation.
Figure 2.
Figure 2.
Advantages of filgotinib use in patients with moderate to severe ulcerative colitis.
See this image and copyright information in PMC

References

    1. Ungaro R, Mehandru S, Allen PB, et al. .. Ulcerative colitis. Lancet Lond Engl 2017;389:1756–1770. - PMC - PubMed
    1. Danese S, Fiorino G, Peyrin-Biroulet L. Positioning therapies in ulcerative colitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2020;18:1280–1290.e1. - PubMed
    1. Singh S, George J, Boland BS, et al. .. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. J Crohns Colitis 2018;12:635–643. - PMC - PubMed
    1. D’Amico F, Peyrin-Biroulet L, Danese S, et al. .. New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming? Curr Opin Pharmacol 2020;55:141–150. - PubMed
    1. D’Amico F, Parigi TL, Fiorino G, et al. .. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Ther Adv Gastroenterol 2019;12:1756284819848631. - PMC - PubMed

Grants and funding